Haldol im fda

Recent studies in the literature show that concomitant use of opioid analgesics and CNS depressants other than benzodiazepines, including alcohol, is also associated with serious adverse events. One study reported that opioid analgesics contributed to 77 percent of deaths where benzodiazepines were determined to be a cause of death, and benzodiazepines contributed to 30 percent of deaths where opioid analgesics were determined to be a cause of death. This study also analyzed the involvement of other CNS depressants (including barbiturates, antipsychotic and neuroleptic drugs, antiepileptic and antiparkinsonian drugs, anesthetics, autonomic nervous system drugs, and muscle relaxants) in these deaths and found that these CNS depressants were contributory to death in many cases where opioid analgesics were also implicated. 5 A second study analyzed 2010 DAWN data and found that alcohol was involved in percent of opioid analgesic abuse-related ED visits and percent of opioid analgesic-related deaths. 6

There are no well controlled studies with HALDOL (haloperidol) in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of HALDOL along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to HALDOL, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment.

The dose of Haldol Decanoate 50 or Haldol Decanoate 100 should be expressed in terms of its haloperidol content. The starting dose of haloperidol decanoate should be based on the patient's age, clinical history, physical condition, and response to previous antipsychotic therapy. The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed. For patients previously maintained on low doses of antipsychotics (. up to the equivalent of 10 mg/day oral haloperidol), it is recommended that the initial dose of haloperidol decanoate be 10–15 times the previous daily dose in oral haloperidol equivalents; limited clinical experience suggests that lower initial doses may be adequate.

Although Haldol continues to be a favored form of chemical restraint in nursing homes, its well-known dangers have not received much attention since the HHS Office of Inspector General issued its well-publicized report in May 2011 about the misuse of atypical antipsychotics in nursing homes . Hopefully this new study will help correct that oversight and serve as the latest of seemingly endless reminders that antipsychotic drugs given to elders with dementia generally do more harm than good and are a very dangerous substitute for actual care.

Haldol im fda

haldol im fda

Although Haldol continues to be a favored form of chemical restraint in nursing homes, its well-known dangers have not received much attention since the HHS Office of Inspector General issued its well-publicized report in May 2011 about the misuse of atypical antipsychotics in nursing homes . Hopefully this new study will help correct that oversight and serve as the latest of seemingly endless reminders that antipsychotic drugs given to elders with dementia generally do more harm than good and are a very dangerous substitute for actual care.

Media:

haldol im fdahaldol im fdahaldol im fdahaldol im fdahaldol im fda